A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart

Michele Miragoli, Siti H. Sheikh Abdul Kadir, Mary N. Sheppard, Nicoló Salvarani, Matilda Virta, Sarah Wells, Max J. Lab, Viacheslav O. Nikolaev, Alexey Moshkov, William M. Hague, Stephan Rohr, Catherine Williamson, Julia Gorelik

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Intrahepatic cholestasis of pregnancy may be complicated by fetal arrhythmia, fetal hypoxia, preterm labor, and, in severe cases, intrauterine death. The precise etiology of fetal death is not known. However, taurocholate has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cardiomyocytes. To identify the underlying reason for increased susceptibility of fetal cardiomyocytes to arrhythmia, we studied myofibroblasts (MFBs), which appear during structural remodeling of the adult diseased heart. In vitro, they depolarize rat cardiomyocytes via heterocellular gap junctional coupling. Recently, it has been hypothesized that ventricular MFBs might appear in the developing human heart, triggered by physiological fetal hypoxia. However, their presence in the fetal heart (FH) and their proarrhythmogenic effects have not been systematically characterized. Immunohistochemistry demonstrated that ventricular MFBs transiently appear in the human FH during gestation. We established two in vitro models of the maternal heart (MH) and FH, both exposed to increasing doses of taurocholate. The MH model consisted of confluent strands of rat cardiomyocytes, whereas for the FH model, we added cardiac MFBs on top of cardiomyocytes. Taurocholate in the FH model, but not in the MH model, slowed conduction velocity from 19 to 9 cm/s, induced early after depolarizations, and resulted in sustained re-entrant arrhythmias. These arrhythmic events were prevented by ursodeoxycholic acid, which hyperpolarized MFB membrane potential by modulating potassium conductance. Conclusion: These results illustrate that the appearance of MFBs in the FH may contribute to arrhythmias. The above-described mechanism represents a new therapeutic approach for cardiac arrhythmias at the level of MFB.

Original languageEnglish
Pages (from-to)1282-1292
Number of pages11
JournalHepatology
Volume54
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Ursodeoxycholic Acid
Fetal Heart
Myofibroblasts
Cardiac Arrhythmias
Cardiac Myocytes
Taurocholic Acid
Fetal Hypoxia
Mothers
Fetal Death
Premature Obstetric Labor
In Vitro Techniques
Membrane Potentials
Heart Diseases
Potassium
Immunohistochemistry
Calcium
Pregnancy

ASJC Scopus subject areas

  • Hepatology

Cite this

Miragoli, M., Sheikh Abdul Kadir, S. H., Sheppard, M. N., Salvarani, N., Virta, M., Wells, S., ... Gorelik, J. (2011). A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. Hepatology, 54(4), 1282-1292. https://doi.org/10.1002/hep.24492

A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. / Miragoli, Michele; Sheikh Abdul Kadir, Siti H.; Sheppard, Mary N.; Salvarani, Nicoló; Virta, Matilda; Wells, Sarah; Lab, Max J.; Nikolaev, Viacheslav O.; Moshkov, Alexey; Hague, William M.; Rohr, Stephan; Williamson, Catherine; Gorelik, Julia.

In: Hepatology, Vol. 54, No. 4, 10.2011, p. 1282-1292.

Research output: Contribution to journalArticle

Miragoli, M, Sheikh Abdul Kadir, SH, Sheppard, MN, Salvarani, N, Virta, M, Wells, S, Lab, MJ, Nikolaev, VO, Moshkov, A, Hague, WM, Rohr, S, Williamson, C & Gorelik, J 2011, 'A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart', Hepatology, vol. 54, no. 4, pp. 1282-1292. https://doi.org/10.1002/hep.24492
Miragoli, Michele ; Sheikh Abdul Kadir, Siti H. ; Sheppard, Mary N. ; Salvarani, Nicoló ; Virta, Matilda ; Wells, Sarah ; Lab, Max J. ; Nikolaev, Viacheslav O. ; Moshkov, Alexey ; Hague, William M. ; Rohr, Stephan ; Williamson, Catherine ; Gorelik, Julia. / A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. In: Hepatology. 2011 ; Vol. 54, No. 4. pp. 1282-1292.
@article{0983ba24ae0942a290cbc6fe17fdcae4,
title = "A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart",
abstract = "Intrahepatic cholestasis of pregnancy may be complicated by fetal arrhythmia, fetal hypoxia, preterm labor, and, in severe cases, intrauterine death. The precise etiology of fetal death is not known. However, taurocholate has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cardiomyocytes. To identify the underlying reason for increased susceptibility of fetal cardiomyocytes to arrhythmia, we studied myofibroblasts (MFBs), which appear during structural remodeling of the adult diseased heart. In vitro, they depolarize rat cardiomyocytes via heterocellular gap junctional coupling. Recently, it has been hypothesized that ventricular MFBs might appear in the developing human heart, triggered by physiological fetal hypoxia. However, their presence in the fetal heart (FH) and their proarrhythmogenic effects have not been systematically characterized. Immunohistochemistry demonstrated that ventricular MFBs transiently appear in the human FH during gestation. We established two in vitro models of the maternal heart (MH) and FH, both exposed to increasing doses of taurocholate. The MH model consisted of confluent strands of rat cardiomyocytes, whereas for the FH model, we added cardiac MFBs on top of cardiomyocytes. Taurocholate in the FH model, but not in the MH model, slowed conduction velocity from 19 to 9 cm/s, induced early after depolarizations, and resulted in sustained re-entrant arrhythmias. These arrhythmic events were prevented by ursodeoxycholic acid, which hyperpolarized MFB membrane potential by modulating potassium conductance. Conclusion: These results illustrate that the appearance of MFBs in the FH may contribute to arrhythmias. The above-described mechanism represents a new therapeutic approach for cardiac arrhythmias at the level of MFB.",
author = "Michele Miragoli and {Sheikh Abdul Kadir}, {Siti H.} and Sheppard, {Mary N.} and Nicol{\'o} Salvarani and Matilda Virta and Sarah Wells and Lab, {Max J.} and Nikolaev, {Viacheslav O.} and Alexey Moshkov and Hague, {William M.} and Stephan Rohr and Catherine Williamson and Julia Gorelik",
year = "2011",
month = "10",
doi = "10.1002/hep.24492",
language = "English",
volume = "54",
pages = "1282--1292",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart

AU - Miragoli, Michele

AU - Sheikh Abdul Kadir, Siti H.

AU - Sheppard, Mary N.

AU - Salvarani, Nicoló

AU - Virta, Matilda

AU - Wells, Sarah

AU - Lab, Max J.

AU - Nikolaev, Viacheslav O.

AU - Moshkov, Alexey

AU - Hague, William M.

AU - Rohr, Stephan

AU - Williamson, Catherine

AU - Gorelik, Julia

PY - 2011/10

Y1 - 2011/10

N2 - Intrahepatic cholestasis of pregnancy may be complicated by fetal arrhythmia, fetal hypoxia, preterm labor, and, in severe cases, intrauterine death. The precise etiology of fetal death is not known. However, taurocholate has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cardiomyocytes. To identify the underlying reason for increased susceptibility of fetal cardiomyocytes to arrhythmia, we studied myofibroblasts (MFBs), which appear during structural remodeling of the adult diseased heart. In vitro, they depolarize rat cardiomyocytes via heterocellular gap junctional coupling. Recently, it has been hypothesized that ventricular MFBs might appear in the developing human heart, triggered by physiological fetal hypoxia. However, their presence in the fetal heart (FH) and their proarrhythmogenic effects have not been systematically characterized. Immunohistochemistry demonstrated that ventricular MFBs transiently appear in the human FH during gestation. We established two in vitro models of the maternal heart (MH) and FH, both exposed to increasing doses of taurocholate. The MH model consisted of confluent strands of rat cardiomyocytes, whereas for the FH model, we added cardiac MFBs on top of cardiomyocytes. Taurocholate in the FH model, but not in the MH model, slowed conduction velocity from 19 to 9 cm/s, induced early after depolarizations, and resulted in sustained re-entrant arrhythmias. These arrhythmic events were prevented by ursodeoxycholic acid, which hyperpolarized MFB membrane potential by modulating potassium conductance. Conclusion: These results illustrate that the appearance of MFBs in the FH may contribute to arrhythmias. The above-described mechanism represents a new therapeutic approach for cardiac arrhythmias at the level of MFB.

AB - Intrahepatic cholestasis of pregnancy may be complicated by fetal arrhythmia, fetal hypoxia, preterm labor, and, in severe cases, intrauterine death. The precise etiology of fetal death is not known. However, taurocholate has been demonstrated to cause arrhythmia and abnormal calcium dynamics in cardiomyocytes. To identify the underlying reason for increased susceptibility of fetal cardiomyocytes to arrhythmia, we studied myofibroblasts (MFBs), which appear during structural remodeling of the adult diseased heart. In vitro, they depolarize rat cardiomyocytes via heterocellular gap junctional coupling. Recently, it has been hypothesized that ventricular MFBs might appear in the developing human heart, triggered by physiological fetal hypoxia. However, their presence in the fetal heart (FH) and their proarrhythmogenic effects have not been systematically characterized. Immunohistochemistry demonstrated that ventricular MFBs transiently appear in the human FH during gestation. We established two in vitro models of the maternal heart (MH) and FH, both exposed to increasing doses of taurocholate. The MH model consisted of confluent strands of rat cardiomyocytes, whereas for the FH model, we added cardiac MFBs on top of cardiomyocytes. Taurocholate in the FH model, but not in the MH model, slowed conduction velocity from 19 to 9 cm/s, induced early after depolarizations, and resulted in sustained re-entrant arrhythmias. These arrhythmic events were prevented by ursodeoxycholic acid, which hyperpolarized MFB membrane potential by modulating potassium conductance. Conclusion: These results illustrate that the appearance of MFBs in the FH may contribute to arrhythmias. The above-described mechanism represents a new therapeutic approach for cardiac arrhythmias at the level of MFB.

UR - http://www.scopus.com/inward/record.url?scp=80053328747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053328747&partnerID=8YFLogxK

U2 - 10.1002/hep.24492

DO - 10.1002/hep.24492

M3 - Article

VL - 54

SP - 1282

EP - 1292

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -